Durvalumab Lengthens Survival in Extensive-Stage SCLC.
Sign Up to like & getrecommendations! Published in 2019 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-nb2019-127
Abstract: In the phase III CASPIAN trial, the PD-L1 inhibitor durvalumab plus standard chemotherapy outperformed chemotherapy alone, extending median overall survival in patients with extensive-stage small cell lung cancer. read more here.
Keywords: durvalumab lengthens; extensive stage; durvalumab; survival extensive ... See more keywords